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Summary
Purpose: Several antiepileptic drugs (AEDs) induce changes in endocrine function in
women with epilepsy. Levetiracetam (LEV) is one of the newer AEDs, and to date no
endocrine side-effects have been reported in humans. However, a recent study on
ovarian follicular cells from prepubertal pigs showed that LEV affected basal steroid
hormone secretion. The aim of the present study was to investigate possible effects of
the drug on endocrine function and ovarian morphology in non-epileptic rats.
Methods: Thirty female Wistar rats were fed per-orally with either 50 mg/kg LEV
(n = 15) or 150 mg/kg LEV (n = 15) twice daily for 90—95 days. Twenty rats received a
control solution. The rats were killed in the dioestrus phase of the oestrous cycle.
Serum concentrations of testosterone, 17b-oestradiol, progesterone, follicle stimu-
lating hormone (FSH), luteinizing hormone (LH) and LEV were measured, and the
ovaries examined histologically.
Results: Mean ovarian weight showed a significant, dose-dependent increase after
LEV treatment. Mean numbers of ovarian follicular cysts were not changed, but the
numbers of corpora lutea and secondary follicles were significantly higher in the
treated animals. Serum testosterone was significantly increased in treated animals
(0.50 nmol/l versus 0.16 nmol/l in controls, p < 0.05), while oestradiol was reduced
(67.4 compared to 257.5 pmol/l in controls, p < 0.05). The low-dose group had* Corresponding author. Tel.: +47 23073580; fax: +47 23074891.
E-mail address: sigrid.svalheim@rikshospitalet.no (S. Svalheim).
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significantly lower serum progesterone concentrations than the control group
(56.8 nmol/l versus 34.7 nmol/l, respectively, p < 0.05). FSH was reduced in the
treated animals (3.3 ng/ml versus 5.5 ng/ml, p < 0.05) while LH was unaffected.
Conclusion: Our findings indicate a possible effect of LEV on the hypothalamic—
pituitary—gonadal (HPG) axis and ovarian morphology in non-epileptic rats. The
effects differ from those previously described for other AEDs. Caution must be taken
before these results can be applied to humans.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Women with epilepsy are at risk of reproductive
health disorders, including menstrual disturbances,
fertility problems, polycystic ovaries and hormonal
changes.1—3 The explanation for this is multifactor-
ial. Epilepsy itself, antiepileptic drugs (AEDs) and
psychosocial factors are all known to affect endo-
crine function.2,4—7 Enzyme-inducing AEDS, such as
phenytoin, carbamazepine and phenobarbital,
reduce the levels of biologically active sex steroid
hormones,2,8,9 while valproate (VPA) has been asso-
ciated with increased occurrence of hyperandrogen-
ism, polycystic ovaries and menstrual disorders.1,10
In animal studies, VPA treatment has been demon-
strated to affect ovarian morphology by increasing
the number of cysts and reducing the number of
corpora lutea in non-epileptic rats.11 In the same
animals, VPA treatment increased testosterone/
oestrogen ratio and decreased oestrogen levels.12
VPA has also been shown to affect steroidogenesis
and inhibit the conversion of testosterone to oes-
tradiol in a series of experiments with cultures of
porcine ovarian follicular cells.13,14
Levetiracetam (LEV) is a relatively new, broad-
spectrum AED with positive reports regarding both
effects and side-effects.15 Recent studies have
shown a promising effect of LEV on generalized
epilepsies like tonic—clonic, absence and myoclonic
epilepsy, for which VPA has previously often been
the drug of choice.16—18 Safety data indicate that
LEV is very well tolerated by the majority of
patients, and endocrine side effects have not been
reported in humans to date.15,19,20 If these data are
confirmed in further studies, LEV may become an
appropriate alternative to VPA for many patients.
This is of particular interest to women within the
fertile age range, for whom VPA has well-known
disadvantages such as reproductive endocrine dis-
orders and teratogenicity.3,21
However, a recent study, utilizing ovarian follicu-
lar cells from prepubertal pigs, demonstrated that
LEV affects basal steroid hormone secretion,22 indi-
cating aneffect of thedrug on steroidogenesis. These
data indicate that LEVmay influence endocrine func-
tion, and this possibility should be explored in bothanimal models and humans before LEV can be recom-
mended as a safe alternative to VPA.
The aim of this study was to investigate possible
effects of long-term LEV treatment on ovarian mor-
phology and sex hormones in female rats. We used
an in vivo model, which has been used to demon-
strate side-effects in other studies of AEDs,12,13,23
and in which it has been possible to extrapolate from
the results of these studies to humans.1,10Methods
Experimental animals and AED
administration
The experiments described were carried out in
agreement with the provisions enforced by the
National Animal Research Authority (NARA).
Sixty-two female Wistar rats (Taconic, Denmark)
were used. The animals were approximately 80
days of age at the beginning of the study. They
were housed in polycarbonate type 4 B&K cages in
groups of three, in a closed system. Beekay bed-
ding (Scanbur BK) was used. Temperature and
humidity were regulated (21  1 8C; 55  10%),
and a 12 h light and darkness schedule used at
an air exchange rate of 20 changes/h. Rats were
fed a standard pellet rat diet, and tap water was
provided ad libitum.
The animals were fed per-orally through a gastric
tube with LEV solution 50 mg/kg (n = 15), 150 mg/kg
(n = 21) or control solution (n = 26) twice daily for
90—95 days. Variations in serum concentrations of
LEV after a single dose were measured by repeated
blood sampling in a subset of the animals (Fig. 1).
The lower dose was chosen to achieve LEV concen-
trations well within the therapeutic range, while
the higher dose was chosen to achieve concentra-
tions slightly above the therapeutic range without
being toxic.
At the end of the study, the animals were killed by
exsanguination under pentobarbital narcosis by
abdominal artery puncture, 3—4 h after the last
dose. Blood was collected, and the serum frozen
at 70 8C until analysed. Internal organs (heart,
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Figure 1 Changes in serum levetiracetam concentrations during the first 6 h after a single dose. Mean concentrations
from six animals in each group are given. Measurements are taken 1, 2, 4 and 6 h after drug administration.kidneys, lungs, liver and ovaries) were collected
from 50 animals. Twelve animals from which inter-
nal organs were to be used for other purposes were
perfusion-fixated according to the method
described by Lehre et al.24 These 12 perfusion-
fixated animals were only used in the morphologic
ovary analyses.
For standardisation of cycle stage at sacrifice,
vaginal smears were taken daily from days 90 to 95,
and the animals were killed as soon as they reached
the dioestrus phase of the oestrus cycle. Vaginal
smears were taken between 06:30 and 08:30 a.m.,
and all animals were killed between 9:00 and 11:00
a.m. Sacrifice was done at random, independent of
treatment groups.
Analyses
Body weight and ovary weight were measured. Tis-
sue samples from the ovaries, liver, kidneys, lungs
and myocardium were fixed in formalin, and sub-
jected to routine procedures for paraffin—wax
embedding. Five micrometers sections were cut
and stained with haematoxylin and eosin for evalua-
tion by light microscopy. A blinded examination of
the ovarian sections was performed and the num-
bers of cysts, follicles and corpora lutea were
counted. The other organs were examined for his-
topathological lesions by routine light microscopic
evaluation.
Testosterone serum levels were determined by
solid-phase radioimmunoassay (RIA) (Coat-A-Count,
Total Testosterone, Diagnostic Products Corpora-
tion, LA, USA). Detection limit was 0.14 nmol/l.17b-Oestradiol concentrations were analysed
using the kit ‘‘Coat-A-Count’’, Oestradiol (Diagnos-
tic Corporation, LA, USA). Detection limit was
50 pmol/l.
Serum levels of progesterone were determined
by solid-phase RIA (Spectria1 Progesterone 125J
Coated Tube RIA, Orion Diagnostica, Espoo, Fin-
land). Detection limit was 0.3 nmol/l. Concentra-
tions of plasma and pituitary luteinizing hormone
(LH) and follicle stimulating hormone (FSH) were
measured by RIA using reagents supplied by the
NIDDK. The reference preparations used were rat
LHRP-1 and rat FSHRP-3, and the minimum detect-
able concentrations were 0.2 and 1.2 ng/ml for LH
and FSH, respectively.
Serum concentrations of LEV were measured by
an isocratic liquid chromatographic method.25
Statistics
Morphological studies: Means and standard devia-
tions for the analyses were calculated. The statis-
tical analyses were performed by one-way ANOVA
and means were compared by Student’s t-test.
Hormonal studies: Non-parametric statistics
were used due to the lack of normal distribution.
Median and quartile deviations (QD: the difference
between the 25 and 75 percentile divided by 2)
are given in Table 3. Statistical analyses were
performed using the Kruskall—Wallis test for mul-
tiple comparisons, followed by Mann—Whitney U-
test. When multiple comparisons were done, Bon-
ferroni corrections for multiple comparisons were
used. A parametric ANOVA analysis was also per-
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data.
Large between-animal variations in hormone con-
centrations were found and indicated that some
animals were not killed in dioestrus as intended.
As there was a possibility that not all animals were
killed in dioestrus phase as intended, the statistical
analyses of the endocrine data were recalculated
after excluding animals in probable heat (oestrogen
values more than 2S.D. above median, and proges-
terone values less than 2S.D. lower than median).
The number of animals excluded from the analyses
was as follows: from the low-dose group, 1/15
animals; from the high-dose group, 4/21 animals;
and from the controls, 5/26.Results
All animals accepted the gastric tube feeding with-
out signs of discomfort or reduced motor activity,
except four (one low dose, three controls) that died
during the experiment period.
Mean LEV concentrations at exsanguination, 4 h
after the last dose, was 122 mmol/l in the low-dose
and 277 mmol/l in the high-dose group (Table 1). A
graph showing variations in serum LEV concentra-
tions after a single dose is provided (Fig. 1). Mean
body weight was the same in all three groups
(Table 1).
Mean ovary weight showed a dose-dependent and
significant increase after LEV treatment (Table 2;
controls versus high dose: p = 0.02). The number of
corpora lutea was significantly higher in all LEV-
treated animals, and in the low-dose group, than
in controls (Table 2; p = 0.045 and 0.034, respec-
tively). In the high-dose group the number of cor-
pora lutea was higher than in the controls, but not
significantly so (Table 2; p = 0.298). The number of
secondary follicles was significantly higher in allTable 1 Animal weight and serum levetiracetam (LEV) con
Parameter Control
Animal weight (mean S.D.) (mg) 253.8 (1
Serum LEV concentrations (mean S.D.) (mmol/l) 0
Table 2 Ovarian morphology after levetiracetam treatmen
Parameter Contr
Ovary weight (mean S.D.) (mg) 94.0 (
Corpora lutea (mean S.D.) (number/section) 9.8 (
Secondary follicles (mean S.D.) (number/section) 6.8 (
Cysts (mean S.D.) (number/section) 0.8 (
* Significantly different from controls ( p  0.05; one-way ANOVALEV-treated animals compared to controls
(Table 2; p = 0.034). The mean number of cysts
per section was lower in the group of LEV-treated
animals than in control animals (Table 2).
Tissue sections from the liver, kidney, lung and
myocardium were examined by light microscopy for
presence of histopathological changes, such as
degeneration, necrosis and inflammation. No such
lesions were observed.
LEV-treated animals differed significantly from
the control group with respect to the serum con-
centrations of several hormones (Table 3). Serum
testosterone concentrations were significantly
higher in LEV-treated animals than in the control
group (Table 3; p = 0.002). Serum oestradiol con-
centrations were significantly lower in LEV-treated
animals than in controls (Table 3; p < 0.001). This
difference was more pronounced in the low-dose
group, which differed significantly from the control
animals ( p < 0.0001), than in the high-dose group,
in which the difference from the control animals was
not significant. Serum progesterone concentrations
were higher after LEV treatment. Again, the differ-
ence was only statistically significant in the low-
dose group (p = 0.045). Serum FSH concentrations
were significantly lower in treated animals than in
controls (p = 0.004 (all animals) and 0.012 (high-
dose group only)). No significant difference was
found in serum LH concentrations between the
different treatment groups. Using a parametric
ANOVA analysis after log transformation of endo-
crine data did not reveal any further significant
values.
A reanalysis of the data, excluding animals which
might not have been exsanguinated during dioes-
trus, did not change the pattern of results, except
for progesterone concentrations, which demon-
strated no significant difference between low-dose
animals and controls following recalculation
(Table 3).centrations
All treated Low dose High dose
5.17) 254.8 (19.87) 253.6 (19.87) 255.6 (22.31)
202 (95.6) 122 (40.9) 277 (65.2)
t
ol All treated Low dose High dose
18.0) 104.1 (21.7) 97,3 (21.5) 110.4x (20.6)
3.0) 11.8* (4.5) 13.3* (5.5) 10.9 (3.5)
2.8) 8.6* (3.5) 8.3 (3.6) 8.8 (3.5)
1.7) 0.4 (1.1) 0.0 (0.0) 0.7 (1.4)
, followed by Student’s t-test).
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Table 3 Serum hormone levels after levetiracetam treatment
Parameter Control All treated Low dose High dose
Testosterone (median QD) (nmol/l)
A 0.16 (0.27) 0.50* (0.19) 0.48 (0.13) 0.52* (0.87)
B 0.08 (0.10) 0.46* (0.10) 0.45* (0.10) 0.47* (0.10)
Oestradiol (median QD) (pmol/l)
A 257.5 (126.8) 67.4* (54.5) 55.8* (14.9) 145.3 (98.7)
B 160.1 (89.6) 62.1* (22.8) 52.9* (12.4) 102.4 (52.0)
Progesterone (median QD) (nmol/l)
A 34.7 (18.1) 47.4 (15.4) 56.8* (26.5) 41.8 (18.4)
B 46.5 (13.8) 53.4 (18.9) 57.6 (25.4) 43.0 (11.8)
FSH (median QD) (ng/ml)
A 5.5 (1.2) 3.3* (0.8) 3.4 (1.3) 3.3* (0.6)
B 5.4 (2.3) 3.2* (0.8) 3.6 (1.2) 3.2 (0.4)
LH (median QD) (ng/ml)
A 1.24 (0.34) 1.31 (0.49) 1.29 (0.31) 1.37 (0.49)
B 1.23 (0.36) 1.27 (0.32) 1.35 (0.33) 1.24 (0.20)
A: all treated animals; B: all treated animals, except those in heat.
* p < 0.05 compared to control. Kruskall—Wallis test for multiple comparisons and Mann—Whitney U-test. Bonferroni corrections
used for comparing low- and high-dose animals with controls.Discussion
These data suggest that long-term LEV-treatment
significantly affects reproductive endocrine func-
tion, aswell as ovarianmorphology, in non-epileptic
rats. The shown endocrine effects of LEV seem to
differ from those previously reported with other
AEDs. The only other AED that has been associated
with morphological changes in the ovary is VPA.
Røste et al.12 demonstrated thatWistar rats treated
with VPA for 90 days had an increased number of
ovarian cysts, a reduced number of corpora lutea,
and reduced ovary weight compared to controls,
which correspond with the findings of polycystic
ovaries in women taking VPA.1,10,26 In the present
study, LEV treatment caused different effects to
these, as ovarian weight and numbers of corpora
lutea increased, whereas the number of cysts
decreased. Also the hormonal changes contrasted
with the findings from the VPA study,12 since there
was no effect of VPA on progesterone or testoster-
one, whilst oestradiol concentrations were
reduced. Gonadotrophins are not affected by VPA
in either humans or animals,1,12 whereas in the
present study FSH was decreased. With respect to
the VPA findingswith the sameexperimentalmodel,
there were close similarities between animal and
human findings.1,10—12
A major problem with all animal studies is how to
extrapolate to the human clinical situation. Extra-
polating to possible clinical implications from ani-
mal studies has obvious limitations, and before this
can be considered a number of questions must beaddressed. Firstly, is the animal model used relevant
to the human situation? Secondly, is the treatment
period sufficient for studying long-term effects?
Thirdly, are the drug concentrations used in the
animal study relevant to the clinical situation?
The laboratory rat has been a major contributor
to our understanding of reproductive biology, not
only in the rat itself, but also in other animals and in
humans.27 Although predictions about drug-related
effects across animal species should be made with
great care, the results presented here clearly
demonstrate the need for further studies on possible
side effects caused by LEV treatment.
It is important that the treatment period is suffi-
cient to mimic long-term drug treatment. In female
rats, 90 days represents about 20 oestrous cycles. In
humans, this number of menstrual cycles would
correspond to approximately 2 years, which is well
above that which has been used as an inclusion
criterion for women participating in studies on
endocrine effects of AEDs.
The therapeutic concentration range for LEV in
humans is between 40 and 130 mmol/l, although
many patients tolerate much higher concentrations.
However, these are trough morning values and
represent the minimum concentration of the ther-
apeutic range during the day. Diurnal fluctuations
are marked for LEV and mean concentrations during
the day are therefore higher than trough morning
levels. In humans using 1000 mg LEV twice daily, the
mean serum concentration after an overnight fast is
70 mmol/l (range: 29—218) and mean Cmax is
188 mmol/l (135—235). In humans using 1500 mg
208 S. Svalheim et al.twice a day, the mean serum concentration is
94 mmol/l (41—200) and mean Cmax is 265 mmol/l
(212—370).28 In our study, human therapeutic con-
centrations of LEV were reached in the rats treated
with the low dose. The animals treatedwith the high
dose of LEV were exposed to drug concentrations
above that commonly used in humans. However, two
daily doses of LEV, as used in this study, indicated
that serum LEV concentrations fluctuate consider-
ably, and the serum LEV concentrations measured in
the high-dose group were only slightly above, or
within, the therapeutic range for most of the day.
We therefore believe that the results observed in
our study were achieved at clinically relevant drug
concentrations, particularly for those animals in the
low-dose treatment group.
The observed effects could be mediated at sev-
eral levels of the hypothalamic—pituitary—gonadal
(HPG) axis. An effect at the hypothalamic—pituitary
level could be argued, because of the lowered FSH
levels. A suppressive effect of LEV on FSH could
affect follicular development and might also disturb
ovarian steroid secretion. The mean plasma testos-
terone concentration was increased approximately
threefold in the present study, and this could be
because testosterone is the principal ovarian secre-
tory product in follicles deprived of FSH. However,
this explanation is not supported by the increased
numbers of corpora lutea and higher progesterone
levels found in LEV-treated animals. It is possible
that the maintained corpus luteum function could
be due to the induction of a pseudo pregnancy-like
state in which corpora lutea are activated by pro-
lactin and persist for up to 13 days before regres-
sing. During this time follicle growth and oestradiol
levels are reduced.29
Consequently, a direct effect of LEV on the ovary
should be considered. This possibility is supported
by the increased basal testosterone and reduced
oestradiol secretion noted with LEV-treatment of
isolated porcine ovarian follicular cells in vitro.23 To
the best of our knowledge there are no other reports
published describing similar effects in vivo.
The data suggest that the LEV effects observed
did not increase with dose. On the contrary, for
several endpoints, changes were actually more pro-
nounced in animals given the lower LEV dose. So far
there is no obvious explanation for this finding.
Methodological errors in the timing of sample and
tissue collection could be suspected, however, there
was consistency between hormonal and morpholo-
gical findings. Further, it is important to be aware
that the dose level used in the low-dose group
(where the greatest effects were seen) resulted in
serum concentrations within the human therapeutic
range.In conclusion, the present study indicates a
drug-specific effect of LEV on reproductive endo-
crine function and ovarian morphology in female
Wistar rats at clinically relevant doses following
long-term drug treatment. Clinical studies on LEV,
however, have not shown any clinical symptoms
indicating endocrine side effects,20,30 and further
studies using both in vivo and in vitro models are
needed to elucidate if, how, and to what degree,
LEV may affect reproductive endocrine functions
in humans.Acknowledgement
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